Combination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study
The combined application of HAICP is an effective regimen for treating patients with UCRLM. HAICP shows superior survival independent of KRAS mutation. In addition, HAICP ameliorates the poor survival observed among KRAS-MUT UCRLM cases.
Authors
- Jin‐He Guo (ORCID: https://orcid.org/0000-0002-4620-2930)
- Fulei Gao (ORCID: https://orcid.org/0000-0002-1785-5246)
- Hao Hu (ORCID: https://orcid.org/0000-0002-7983-7377)
- Rong Liu (ORCID: https://orcid.org/0000-0001-5170-6474)
- Maohuan Lin
- Jiachang Chi
Institutions
- Shanghai Medical College of Fudan University (CN)
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Nantong University (CN)
- Renji Hospital (CN)
- Affiliated Hospital of Nantong University (CN)
- Health First (US)
- Sun Yat-sen Memorial Hospital (CN)
- Zhongda Hospital Southeast University (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Journal of Cancer Research and Therapeutics
- Published
- 2025-09-01
- DOI
- https://doi.org/10.4103/jcrt.jcrt_1869_23
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00